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The communication of risk is an important and often difficult
aspect of clinical practice. This clinical review aims to provide
practising clinicians with a comprehensive and up to date
overview of current evidence in this developing area.
What is risk communication?
Risk is the probability that a hazard will give rise to harm.1Risk
communication is defined as the open two way exchange of
information and opinion about harms and benefits, with the aim
of improving the understanding of risk and of promoting better
decisions about clinical management.2 Risk communication
should therefore cover the probability of the risk occurring, the
importance of the adverse event being described, and the effect
of the event on the patient.3
Risk messages are common. We hear that “there is a risk of
flooding” or “the terrorism threat level is orange.” In medicine,
we may tell people that their “risk of a heart attack is 15%” or
“stopping smoking will reduce their risk of lung cancer,” but
what do clinicians hope to achieve by providing this
information? Box 1 outlines a clinical scenario that requires
effective risk communication.
Communicating risk involves providing the patient with a
balanced evidence based summary of the risks and harms
associated with a service, test, or treatment.3 InMs Jones’s case,
it would be important to deal with her personal risk of breast
cancer (based on her risk factors) and how this risk compares
with the general population. Tomake an informed decision, she
would also need to know whether screening would reduce the
risk of an adverse outcome should she develop breast cancer
and how this reduction in risk compares with no screening. She
would also need to know the harms of screening. The clinician
should present this information to her in the most transparent
and understandable (rather than persuasive) way and accept that
her informed decision on her own care may not necessarily be
the one that reduces her risk. This highlights the complexities
of risk communication. People perceive risk differently
depending on their awareness and understanding of the risk in
question and also depending on the way the risk information is
presented to them.1 Therefore, effective risk communication
should involve the sharing of information that improves risk
perception and understanding and that allows shared decision
making. Sometimes this may be at odds with apparent “public
health” messages that may, for example, promote uptake of
screening tests to achieve programme effectiveness at population
levels. However, the clinician should accept that the final
decision depends as much on the patient’s own values as it does
on the risk information presented.
The literature on risk communication is diverse and some areas
of risk communication are still without strong evidence.4 This
review discusses the importance of effective risk communication
and summarises the evidence behind the various methods of
presenting risk information.
Why is risk communication important?
Where there is good evidence of the benefits of an intervention,
risk communication should aim to go beyond simply sharing
information and endeavour to change beliefs or promote
behavioural change.4 This is achievable, because theories of
behavioural change highlight the association between risk
perception (belief about the likelihood of personal harm from
any given “risk”) and health related behaviour.5 For example,
adults who think that they are at high risk of an illness (such as
influenza) are more likely than others to take up vaccination.6
However, many healthcare decisions have no single “best
treatment” and require trade-offs between harms and benefits.7
The provision of risk information in these scenarios should
therefore promote patient involvement, informed decision
making, and shared management plans.
How risk information is presented (for example, graphically,
visually, verbally) is important and influences the degree to
which perceived risk will affect behavioural change, such as
with cardiovascular risk information.8 9 Attention is needed not
just on accurately predicting cardiovascular risk but also on how
best to present that risk, stimulate changes in health behaviour,
and reduce risk levels. Risk communication is important because
it is something that most clinicians do every day. If done
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Summary points
Risk communication is the open two way exchange of information and opinion about harms and benefits; it aims to improve understanding
of risk and promote better decisions about clinical management
Strong evidence suggests that the format in which risk information is presented affects patients’ understanding and perception of risk
There is emerging evidence that effective risk communication can lead to more informed decision making in screening
Decision aids can be an effective adjunct to risk communication and can improve knowledge, awareness, and decision making
The presentation of data uncertainty is one of the most difficult aspects of risk communication
Box 1 Ms Jones’s dilemma
Ms Jones has just celebrated her 50th birthday. She is fit and well and takes no regular drugs. She comes to the surgery to discuss
mammography screening. Ms Jones has no family history of cancer, had her first period aged 14 years, and her first child aged 26. Her
sister has told her that a mammogram will detect a cancer before she feels a lump, so that any cancer will be diagnosed earlier, which “can
only be a good thing.” Ms Jones is more sceptical, having read stories in the press of women who had mammograms and biopsies and were
then told it was a “false alarm.” She wishes to know more about the benefits and harms of mammography screening before making a final
decision.
Sources and selection criteria
We are updating a Cochrane systematic review on risk communication in screening. Published studies and review papers identified during
the search period for this review (2008-2011) were consulted for this article. We also searched PubMed and the Cochrane library for primary
research articles, systematic reviews, and commentaries by authoritative authors in the field of risk communication published in the past 12
months.
effectively it can trigger changes in beliefs or behaviour, but
for this to occur the risk has to be communicated effectively.
How good (or bad) are clinicians at
communicating risk?
Risk communication research has focused more on what we are
doing rather than on howwell we are doing it. An observational
study of 70 consultations in primary care reported that
cardiovascular risk was mainly communicated using verbal
qualifiers (telling patients that their risk is “high,” “medium,”
or “low”), but that patients’ subjective understanding was
significantly higher when visual formats were used.10Qualitative
research reported that a sample of gynaecologists in Germany
often did not correctly explain the benefits and harms of
mammography screening to women.11 Further work by
Gigerenzer and colleagues highlights doctors’ difficulties with
explaining positive predictive values of mammography,
interpreting risks associated with the use of the contraceptive
pill, and understanding survival rates for cancer.12 13
Barriers to effective risk communication
Effective risk communication can be difficult to achieve for
many reasons. The most commonly reported reason is the
difficulty that patients and doctors have understanding
numbers.12-15 Gigerenzer coined the term “collective statistical
illiteracy” to describe how doctors, patients, journalists,
politicians, and society at large have trouble understanding and
interpreting health statistics.12 Basic numeracy is also a
problem—for example, only 21% of a sample of highly educated
American adults could correctly identify one in 1000 as being
equivalent to 0.1%.14 Clinicians need to be adept at
understanding numbers and explaining them in a way that
patients can comprehend.
Methods available to communicate risk
Risk information can be communicated using several different
methods and formats. Here we summarise these methods,
provide examples, and discuss recent advances in the evidence
base for their use.
Framing
“Framing manipulation” is the presentation of logically
equivalent information in different ways.16 It can be further
subdivided into “attribute framing” and “goal framing.”
Attribute framing is the positive versus negative description of
a specific attribute of a single item or state. For example, Ms
Jones could be told that there is an 82% chance that she will
survive for five years after a diagnosis of breast cancer (positive
attribute framing), or that she has an 18% chance of dying within
five years of such a diagnosis (negative attribute framing). Akl
and colleagues systematically reviewed 35 trials of positive
versus negative attribute framing for their effects on cognitive
and behavioural outcomes.17 Interventions were perceived as
more beneficial when presented using positive framing
messages, but there was little evidence that framing affected
patients’ understanding or behaviour.
Goal framing describes the consequences of performing or not
performing an act, presented as a gain versus a loss. For
example, “screening will improve your chance of survival from
cancer” versus “not participating in screening will reduce your
chance of survival from cancer.” Patients perceived screening
as more effective when presented with a loss message, but again
there was no evidence of an effect on patients’ understanding
or behaviour.17
Presenting risk reduction
Risk reduction can be presented using relative risk reduction
(RRR), absolute risk reduction (ARR), or numbers needed to
treat (NNT).
The RRR is the reduction of risk in the intervention group
relative to the risk in the control group. For a risk of 20% in the
control group and a risk of 10% in the intervention group, the
RRRwould be 50%. The ARR is the difference in risks between
two groups, which for these same figures would be 10%. The
NNT is the number of patients who need to be treated (or
screened) to prevent one additional adverse outcome (NNT=10
for the above figures).
Ms Jones could be presented with the following statements18 19:
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• RRR: Early detection with mammography reduces the risk
of dying from breast cancer by 15%
• ARR: Early detection with mammography reduces the risk
of dying from breast cancer by 0.05%
• NNT: 2000women need to have regular mammograms for
more than 10 years to prolong one life.
A recent review of evidence suggested that using RRR makes
treatment benefits and changes in risk seem larger than they are
and recommended that information on risk reduction be
consistently presented using ARR.20 A Cochrane systematic
review compared the use of ARR, RRR, and NNT in 35 trials.21
No studies reported effects of using these risk reduction formats
on patients’ decisionmaking or behaviour. The review did assess
effects on patients’ objective understanding, perception of
benefit, and persuasiveness. It concluded that:
• RRR and ARR are equally well understood and both
formats are better understood by patients and clinicians
than is NNT
• RRR is perceived to be larger and is more persuasive than
ARR and NNT
• ARR is perceived to indicate a larger effect than when the
same information is expressed using NNT but is no more
persuasive.
Personalising risk information
The risk of breast cancer can be presented as a general
population based risk estimate (generalised risk information)
or on the basis of the individual’s own risk factors (personalised
risk information). Personalised risk information can be presented
as an absolute risk or as a numerical estimate of risk; it can
categorise the individual as belonging to high, medium, or low
risk groups; or it may simply list the individual’s risk factors.
Because personalised risk information is based on the
individual’s own characteristics, it is thought to provide a more
accurate picture of risk and to improve decision making.22 A
risk tool (such as www.cancer.gov/bcrisktool; fig 1⇓) could be
used to provide Ms Jones with her personalised risk of
developing invasive breast cancer. Several tools are also
available for calculating cardiovascular risk, such as QRISK
(http://qrisk.org).
A Cochrane review of 22 randomised controlled trials suggests
that, compared with general risk information, personalised risk
communication (whether written, spoken, or visually presented)
in the context of screening tests can lead to more accurate risk
perception, improved knowledge, and increased uptake of
screening tests.22 Since the publication of that review, three
randomised controlled trials have shown that providing
personalised risk information leads to more informed decision
making about participation in colorectal cancer and prenatal
screening.23-25
Natural frequencies
A natural frequency is a joint frequency of two events, such as
the number of women with breast cancer who have a positive
mammogram.26
The use of natural frequencies, rather than percentages or
probabilities, probably improves understanding of risks and
benefits.26 27 Akl and colleagues showed that clinicians and
patients find natural frequencies easier to understand than
probabilities, suggesting that decisions based on frequencies
are more informed than those based on probabilities.21 There is
also growing evidence to support the use of pictographs (fig
2⇓) to present natural frequencies, with evidence suggesting
that these are well understood and that they effectively support
communication about individual statistics.8 20
Decision aids
Decision aids aim to help patients participate in healthcare
decisions by providing clear evidence based information on the
choices available. They should communicate the benefit and
harm of each option and promote informed decision making. A
systematic review of 86 randomised controlled trials found that
the use of decision aids improves patient knowledge and risk
perception and increases patients’ participation in decision
making, promoting informed decision making that is consistent
with patient values.28 This review also suggested that although
decision aids can improve patient-doctor communication, they
have not been shown to improve actual health outcomes.
Another systematic review of randomised controlled trials
showed that decision aids can also increase the clinician’s
adoption of shared decision making.29
Although there is good evidence to support the cognitive benefits
of decision aids, evidence for behavioural change is weaker.
One systematic review suggested that decision aids have variable
effects on patient behaviour.28 For certain decisions, patients
exposed to a decision aid behaved differently from those who
did not use a decision aid. For example, patients exposed to a
decision aid were less likely to opt for prostate specific antigen
screening (risk ratio 0.85, 95% confidence interval 0.74 to 0.98).
However, for other decisions (such as participating in colorectal
screening), there was no evidence to suggest that patients
exposed to the decision aid behaved any differently from those
who were not.
An increasing number of online decision aids include risk
communication elements, such as for decisions about screening
(for example, prostate specific antigen testing; www.prosdex.
com), surgical treatment (for example, choosing between breast
conserving surgery or mastectomy for breast cancer; www.
bresdex.com; fig 3⇓), or medication (for example, choosing to
take a statin; www.npc.nhs.uk). Clinicians’ use of these aids
during consultations could increase shared decision making and
improve patients’ knowledge and understanding. Furthermore,
patients who use decision aids are consistently more ready to
make a decision than those receiving usual care.28 In the case
of Ms Jones, she could be directed to the breast screening
decision aid above to help her reach an informed decision about
whether to participate in mammography screening (box 2).
Uncertainty
Other areas of risk communication remain inconclusive,
including the quantity of information that should be presented,
the order in which to present information, the use of summary
tables, and best practice on presenting risk information when
the evidence base is unclear. The presentation of uncertainty
about data has been highlighted as one of the most difficult
elements of risk communication,30 and empirical research studies
are still needed in this area. Politi and colleagues report the
problems of communicating uncertainty in a narrative review.30
They highlight the conceptual differences in the definition of
uncertainty and in its measurement. The available research
suggests that the response to uncertainty depends very much on
the clinician’s and patient’s personal characteristics and values.
Cross sectional surveys suggest that the communication of
scientific uncertainty about medical tests and treatments depends
on doctors’ perceptions of their patients’ reaction to
uncertainty.31 Further research also suggests that patients are
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e3996 doi: 10.1136/bmj.e3996 (Published 18 June 2012) Page 3 of 7
CLINICAL REVIEW
Box 2 Helping Ms Jones to make an informed decision
The NHS National Prescribing Centre (www.npc.nhs.uk) provides a breast screening decision aid. This explains that if 1000 women aged
50-70 years attend regular mammography screening for 10 years, 970 women will not have breast cancer, although 130 of these women
will have undergone unnecessary extra investigations. Thirty women will have breast cancer diagnosed. Of these 30 women:
• In four, the breast cancers would have been clinically inconsequential
• In 23 of these women, the fact that the breast cancer was picked up by screening will have no effect on their outcome
• Three women will live longer because their breast cancer was detected early through screening
unclear about the degree of uncertainty in medical decisions,
with 39% of 2944 American adults believing that the Food and
Drug Administration approves only “extremely effective”
drugs.32 Communicating uncertainty may also lead to lower
decision satisfaction among patients.33
The degree of scientific uncertainty that complicates medical
decision making can be highlighted using the example of Ms
Jones. Is it appropriate to present Ms Jones with the risk of
breast cancer in the UK using a prevalence estimate? Should
we provide her with confidence limits for the prevalence
estimate so that she can see the uncertainty associated with the
estimate? When we informed Ms Jones that “mammography
would reduce her risk of breast cancer by 15%,” should we also
have discussed the strength and validity of the research that the
review was based on? For example, when the review looked
only at adequately randomised trials, outcome did not differ
between patients who underwent screening and controls.18
Numerical literacy and understanding are even more important
when communicating data uncertainty, and the clinician needs
to balance information provision with the understanding and
knowledge needed to make a decision. In an attempt to achieve
this aim, several methods have been adopted, but there is little
evidence for their effectiveness.30 The most commonly used
method is to summarise the quality of evidence pertaining to a
given health intervention using a rating system and simple
descriptive terms to describe the degree of uncertainty (fig 4⇓).
In summary, evidence suggests that ARR is a more balanced
and understandable representation of risk reduction for patients
and clinicians than RRR or NNT. Natural frequencies are easier
to understand and interpret than percentages or probabilities.
Emerging evidence supports the use of personalised risk
communication for promoting informed decision making in
screening. There is also good evidence to support decision aids
as a practical support to risk communication. Finally, it is
difficult to communicate data uncertainty; there is little clear
guidance on best practice approaches, and this area needs further
empirical research.
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Questions for future research
Can effective risk communication lead to behavioural change when the evidence supports specific outcomes?
Are there methods of presenting data uncertainty that can improve understanding, knowledge, and decision making?
Tips for non-specialists
Become familiar with tools that provide decision support for common consultations and use them as adjuncts to normal consulting
Consider using absolute risks when discussing risk reduction with patients
Direct patients to decision aids for interventions where more than one option is available and informed decision making depends on
patients’ personal preferences and values
Additional educational resources
Resources for healthcare professionals
NHS National Prescribing Centre (www.npc.nhs.uk/patient_decision_aids/)—Large number of freely available patient decision aids that
can be downloaded, printed, and used during consultations
Resources for patients
Option Grids (www.optiongrid.co.uk/)—“Option grids” are brief tools that describe options for several commonly encountered healthcare
decisions
Patient UK (www.patient.co.uk/search.asp?searchterm=brief+decision+aid&searchcoll=All&x=0&y=0)—Brief decision aids for a variety
of conditions
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Figures
Fig 1 Calculating Ms Jones’s risk of invasive breast cancer using her personal risk factors
Fig 2 The NHS National Prescribing Centre provides pictographs to help explain the reduction in cardiovascular risk from
taking statins in people with a moderate risk of a cardiovascular event (20% over 10 years). For more details see
www.npc.nhs.uk
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e3996 doi: 10.1136/bmj.e3996 (Published 18 June 2012) Page 6 of 7
CLINICAL REVIEW
Fig 3 Breast Cancer Decision Explorer (BresDex; www.bresdex.com). A decision aid to help women with breast cancer
choose between mastectomy and breast conserving surgery
Fig 4 Presenting data uncertainty. Categories of evidence: an approach used by the BMJ Clinical Evidence series7
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